Cargando…

Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab

To evaluate whether inhibition of the proinflammatory cytokines IL-1β or IL-17A by canakinumab or secukinumab, respectively, influence the signs and symptoms of dry eye. METHODS: In a randomized, double-masked, placebo-controlled, outpatient clinical trial, 72 patients with moderate to severe dry ey...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grosskreutz, Cynthia L., Hockey, Hans-Ulrich, Serra, Denise, Dryja, Thaddeus P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cornea 2015
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633966/ https://www.ncbi.nlm.nih.gov/pubmed/26418434 http://dx.doi.org/10.1097/ICO.0000000000000627

Ejemplares similares

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections
por: Kammüller, Michael, et al.
Publicado: (2017)

Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV
por: Bedier, Helbies, et al.
Publicado: (2023)

The Functions of IL-23 and IL-2 on Driving Autoimmune Effector T-helper 17 Cells into the Memory Pool in Dry Eye Disease
por: Chen, Yihe, et al.
Publicado: (2020)

Protective effect of Secukinumab on severe sepsis model rats by neutralizing IL-17A to inhibit IKBα/NFκB inflammatory signal pathway
por: Wang, Xingsheng, et al.
Publicado: (2022)

The IL-1 inhibitor Canakinumab for Familial Mediterranean Fever: the Greek experience in 12 patients
por: Laskari, K, et al.
Publicado: (2015)

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
por: Kosmidis, Michalis L., et al.
Publicado: (2019)

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor
por: Pelechas, Eleftherios, et al.
Publicado: (2017)

Discrepancies in Persistent Dry Eye Signs and Symptoms in Bilateral Pseudophakic Patients
por: Hanyuda, Akiko, et al.
Publicado: (2019)

An experience of use of canakinumab IL-1 inhibitor in children with cryopyrin-associated periodic syndromes (CAPS)
por: Salugina, Svetlana O, et al.
Publicado: (2014)

Dynamics of Adaptive Immune Cell and NK Cell Subsets in Patients With Ankylosing Spondylitis After IL-17A Inhibition by Secukinumab
por: Jiang, Yutong, et al.
Publicado: (2021)

Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab
por: Nikolakis, Georgios, et al.
Publicado: (2021)

IL-17 Producing Lymphocytes Cause Dry Eye and Corneal Disease With Aging in RXRα Mutant Mouse
por: Alam, Jehan, et al.
Publicado: (2022)

Conjunctiva Resident γδ T Cells Expressed High Level of IL-17A and Promoted the Severity of Dry Eye
por: Li, Ling, et al.
Publicado: (2022)

Upregulation of the IL-33/ST2 pathway in dry eye
por: Wang, Shudan, et al.
Publicado: (2019)

Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F
por: Adams, Ralph, et al.
Publicado: (2020)

Serum concentrations of IL-17A, IL-17B, IL-17E and IL-17F in patients with systemic sclerosis
por: Robak, Ewa, et al.
Publicado: (2019)

The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
por: Tzimouli, V, et al.
Publicado: (2008)

New-Onset Crohn's Disease following Initiation of Secukinumab: A Case Report and Review of the Role of IL-17 in the Pathogenesis of Crohn's Disease
por: Khouri, Anas, et al.
Publicado: (2023)

Effect of Lutein on Ocular Goblet Cell, IFN-γ, and IL-17 Concentration in Dry Eye-Induced Mice Model
por: Faustine, Giovani, et al.
Publicado: (2023)

IL-17-induced dimerization of IL-17RA drives the formation of the IL-17 signalosome to potentiate signaling
por: Goepfert, Arnaud, et al.
Publicado: (2022)

Response to IL‐17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein‐coding and untranslated regions of the IL‐17A gene: results from a multicentre study of four European psoriasis cohorts
por: van Vugt, L.J., et al.
Publicado: (2019)

New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function
por: Saviano, Anella, et al.
Publicado: (2023)

IL-17A, IL-17RC polymorphisms and IL17 plasma levels in Tunisian patients with rheumatoid arthritis
por: Dhaouadi, Tarak, et al.
Publicado: (2018)

The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond
por: Brembilla, Nicolo Costantino, et al.
Publicado: (2018)

IL-17 and IL-17-producing cells in protection versus pathology
por: Mills, Kingston H. G.
Publicado: (2022)

Controlled Mycobacterium tuberculosis infection in mice under treatment with anti-IL-17A or IL-17F antibodies, in contrast to TNFα neutralization
por: Segueni, Noria, et al.
Publicado: (2016)

Early IL-17A Prevention Rather Than Late IL-17A Neutralization Attenuates Toluene Diisocyanate-Induced Mixed Granulocytic Asthma
por: Chen, Shuyu, et al.
Publicado: (2022)

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics
por: Ait-Oudhia, S, et al.
Publicado: (2012)

Real-World Persistence and Treatment Patterns in Patients with Psoriatic Arthritis Treated with Anti-IL17 Therapy in Spain: The PerfIL-17 Study
por: Joven, Beatriz, et al.
Publicado: (2023)

Regulatory effects of C5a on IL-17A, IL-17F, and IL-23
por: Grailer, Jamison J., et al.
Publicado: (2013)

Interleukin (IL)-12 and IL-18 Synergize to Promote MAIT Cell IL-17A and IL-17F Production Independently of IL-23 Signaling
por: Cole, Suzanne, et al.
Publicado: (2020)

IL17F Expression as an Early Sign of Oxidative Stress-Induced Cytotoxicity/Apoptosis
por: Bauer, Mario, et al.
Publicado: (2022)

Cytokines (interleukin-9, IL-17, IL-22, IL-25 and IL-33) and asthma
por: Farahani, Rahim, et al.
Publicado: (2014)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Pivotal Roles of T-Helper 17-Related Cytokines, IL-17, IL-22, and IL-23, in Inflammatory Diseases
por: Qu, Ning, et al.
Publicado: (2013)

Involvement of IL17A, IL17F and IL23R Polymorphisms in Colorectal Cancer Therapy
por: Omrane, Inés, et al.
Publicado: (2015)

The Emerging Role of the IL-17B/IL-17RB Pathway in Cancer
por: Bastid, Jérémy, et al.
Publicado: (2020)

Dual inhibition of IL-17A and IL-17F in psoriatic disease
por: Iznardo, Helena, et al.
Publicado: (2021)

Clinical Significance of IL-23 Regulating IL-17A and/or IL-17F Positive Th17 Cells in Chronic Periodontitis
por: Luo, Zhenhua, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_hbqjsvdh98dle4e17hv8crps68